Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 9/20 | 0.42 |
| ▸ | NNMT | P40261 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.38 |
| ▸ | MC5R | P33032 | 1/20 | 0.38 |
| ▸ | MC3R | P41968 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24094538 | 0.87 | MC4R (0.35) | MC4RKCNH2FFAR4MAOBNPC1 | |
| SCHEMBL30340511 | 0.86 | MC4R (0.41) | MC4RNNMTKCNH2MC5RMC3R | |
| SCHEMBL30318715 | 0.86 | MC4R (0.41) | MC4RNNMTKCNH2MC5RMC3R | |
| SCHEMBL24094514 | 0.86 | MC4R (0.41) | MC4RNNMTKCNH2MC5RMC3R | |
| SCHEMBL24094529 | 0.86 | MC4R (0.41) | MC4RNNMTKCNH2MC5RMC3R | |
| SCHEMBL24854145 | 0.86 | MC4R (0.41) | MC4RNNMTKCNH2MC5RMC3R | |
| SCHEMBL24094501 | 0.85 | NNMT (0.42) | MC4RNNMTKCNH2MEN1PABPC1 | |
| SCHEMBL24094537 | 0.83 | MT-CO2 (0.37) | MC4RMEN1KMT2AMAPK8MAOB | |
| SCHEMBL24853327 | 0.82 | NNMT (0.42) | NNMTMEN1PABPC1KMT2AMAPT | |
| SCHEMBL24853342 | 0.82 | NNMT (0.42) | MC4RNNMTMEN1PABPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084084-A1 | Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one | PFIZER INC. (US) | 2025-03-13 | — | — | US | disclosed |
| WO-2024255412-A1 | SPIRO HETEROCYCLIC COMPOUND AND USE THEREOF | 广州必贝特医药股份有限公司 | 2024-12-19 | — | — | WO | disclosed |
| EP-4161927-B9 | SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER (US) | 2024-11-06 | — | — | EP | disclosed |
| EP-4161927-B1 | SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20230174532-A1 | METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR | PFIZER INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174532-A1 | METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR | PFIZER INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174532-A1 | METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR | PFIZER INC. (US) | 2023-06-08 | — | — | US | disclosed |
| CN-116113635-A | Spiro compounds as melanocortin 4 receptor antagonists and uses thereof | 辉瑞公司 | 2023-05-12 | — | — | CN | disclosed |
| US-11643412-B2 | Melanocortin 4 receptor antagonists and uses thereof | PFIZER INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643412-B2 | Melanocortin 4 receptor antagonists and uses thereof | PFIZER INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643412-B2 | Melanocortin 4 receptor antagonists and uses thereof | PFIZER INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20230019853-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230019853-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2023-01-19 | — | — | US | disclosed |
| WO-2023275715-A1 | METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS | PFIZER INC. (US) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084084-A1 | Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one | CSPP1, PRNP, RPLP2 | MC4R 2861/4885NNMT 3779/4885KCNH2 540/4885 |
| US-20230019853-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | MC4R, MC3R, MC5R | MC4R 1/4885NNMT 3218/4885KCNH2 3177/4885 |
| US-20230174532-A1 | METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR | MC4R, MC2R, NPY4R | MC4R 1/4885NNMT 1576/4885KCNH2 3858/4885 |
| US-11643412-B2 | Melanocortin 4 receptor antagonists and uses thereof | MC4R, MC3R, MC5R | MC4R 1/4885NNMT 3218/4885KCNH2 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.